MediciNova, Inc. (MNOV) reported yesterday that preliminary results from a hospital emergency department (ED)-based Phase 2b clinical trial evaluating its MN-221 in patients with acute exacerbations of asthma did not statistically meet the primary endpoint, improvement in FEV1 (Forced Expiratory Volume in One Second) compared to placebo. MediciNova’s stockholders clearly reacted on these disappointed results: MNOV […]